



➤ **Levemir discontinuation – process for changing patients to an alternative insulin.**

Levemir® (insulin detemir) FlexPen 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill 100units/ml solution for injection 3ml cartridges are being discontinued. Stock is anticipated to last until 31st December 2026. The UHN diabetes team have contacted all GP practices in Northamptonshire to support with transitioning of patients on Levemir to an alternative insulin. Please ensure your practice responds to this email, even if you would like to decline the support offer. This UHN service will support with transitioning more complex patients currently prescribed Levemir. It is the responsibility of the practice to review and transition the less complex patients to an alternative insulin. If the UHN diabetes team support offer is declined or not responded to, it will be the responsibility of the practice to ensure all patients are transitioned to an alternative insulin. Please refer to the [NICB guidance](#) for support with switching patients on Levemir. Please contact the Medicines Optimisation Team with any queries: northantsicb.medicinesoptimisationteam@nhs.net

➤ **Denosumab 60mg injection formulary status**

Denosumab 60mg injection changed formulary status in August 2025, from Amber (shared care) to Green Specialist Initiated. Secondary care initiate therapy and request the GP to continue ongoing prescribing and administration. A shared care protocol is not required. Most existing patients will have been receiving Prolia® brand. Clinicians at the University Hospitals of Northamptonshire (UHN) are initiating new patients on Ponlimsi® brand of biosimilar denosumab injection. It is currently being considered if patients currently receiving Prolia® brand in primary care could be switched to Ponlimsi®. Prescriptions must be written by brand so there is a record of the product given.

Denosumab 60mg injection is administered every 6 months. There have been reports of some patients not receiving their continuation in primary care. Please ensure there is a process in place to enable the continuation of therapy in primary care 6 months after secondary care have given the first dose.

➤ **Updates on seasonal vaccinations programmes**

NHS England has published the first version of their Seasonal Vaccination Provider Programme Guide for autumn/winter 2026/27 on the [NHS Futures](#) platform (login required). The guide brings together the key operational information required for GP practices and community pharmacies related to the adult flu, COVID-19 and children's flu programmes. It includes the addition of people experiencing homelessness, to the flu vaccination service specifications and the requirement to use the 'Record a Vaccination Service (RAVS)' IT system to record all NHS vaccinations from 1st September. Updated versions of the guide will be published at the above web address throughout the season, so clinicians should always refer to the latest version.

➤ **Orforglipron now available privately**

Orforglipron (Foundayo) is now available to be prescribed **privately** for type 2 diabetes and weight management. NICE guidance on its use for weight management is expected in November.